AU2022416644B2 - Solid forms of pyrazolo[3,4-d]pyrimidine compounds - Google Patents

Solid forms of pyrazolo[3,4-d]pyrimidine compounds

Info

Publication number
AU2022416644B2
AU2022416644B2 AU2022416644A AU2022416644A AU2022416644B2 AU 2022416644 B2 AU2022416644 B2 AU 2022416644B2 AU 2022416644 A AU2022416644 A AU 2022416644A AU 2022416644 A AU2022416644 A AU 2022416644A AU 2022416644 B2 AU2022416644 B2 AU 2022416644B2
Authority
AU
Australia
Prior art keywords
solid form
approximately
certain embodiments
solid
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022416644A
Other languages
English (en)
Other versions
AU2022416644A1 (en
Inventor
John C. Amedio Jr.
Caroline Yvette PROULX-LAFRANCE
Erika Volckova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2022416644A1 publication Critical patent/AU2022416644A1/en
Application granted granted Critical
Publication of AU2022416644B2 publication Critical patent/AU2022416644B2/en
Priority to AU2025275149A priority Critical patent/AU2025275149A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2022416644A 2021-12-16 2022-12-16 Solid forms of pyrazolo[3,4-d]pyrimidine compounds Active AU2022416644B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025275149A AU2025275149A1 (en) 2021-12-16 2025-12-03 Solid forms of pyrazolo[3,4-d]pyrimidine compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163290136P 2021-12-16 2021-12-16
US63/290,136 2021-12-16
PCT/US2022/081795 WO2023114995A1 (en) 2021-12-16 2022-12-16 Solid forms of pyrazolo[3,4-d]pyrimidine compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025275149A Division AU2025275149A1 (en) 2021-12-16 2025-12-03 Solid forms of pyrazolo[3,4-d]pyrimidine compounds

Publications (2)

Publication Number Publication Date
AU2022416644A1 AU2022416644A1 (en) 2024-07-04
AU2022416644B2 true AU2022416644B2 (en) 2025-09-11

Family

ID=85172741

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022416644A Active AU2022416644B2 (en) 2021-12-16 2022-12-16 Solid forms of pyrazolo[3,4-d]pyrimidine compounds
AU2025275149A Pending AU2025275149A1 (en) 2021-12-16 2025-12-03 Solid forms of pyrazolo[3,4-d]pyrimidine compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025275149A Pending AU2025275149A1 (en) 2021-12-16 2025-12-03 Solid forms of pyrazolo[3,4-d]pyrimidine compounds

Country Status (11)

Country Link
US (2) US12012412B2 (https=)
EP (1) EP4448529A1 (https=)
JP (1) JP2024546844A (https=)
KR (1) KR20240119299A (https=)
CN (1) CN118401525A (https=)
AU (2) AU2022416644B2 (https=)
CA (1) CA3242577A1 (https=)
IL (1) IL313314A (https=)
MX (1) MX2024007517A (https=)
TW (1) TW202333676A (https=)
WO (1) WO2023114995A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12012412B2 (en) * 2021-12-16 2024-06-18 Pfizer Inc. Solid forms of pyrazolo[3,4-d]pyrimidine compounds
AU2024329573A1 (en) * 2023-08-22 2026-04-02 Cardurion Pharmaceuticals, Inc. Pyrazolo[3,4-d]pyrimidinone compounds for the treatment of chronic heart failure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008139293A1 (en) * 2007-05-11 2008-11-20 Pfizer Inc. Amino-heterocyclic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CN109893653A (zh) * 2017-12-11 2019-06-18 王慧敏 Pde9抑制剂的新用途
US12012412B2 (en) 2021-12-16 2024-06-18 Pfizer Inc. Solid forms of pyrazolo[3,4-d]pyrimidine compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008139293A1 (en) * 2007-05-11 2008-11-20 Pfizer Inc. Amino-heterocyclic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Verhoest, P.R. et al.; J. Med. Chem., 55, p.9045-9054 (2012); DOI: 10.1021/jm3007799 *

Also Published As

Publication number Publication date
MX2024007517A (es) 2024-08-19
AU2022416644A1 (en) 2024-07-04
NZ812114A (en) 2025-08-29
AU2025275149A1 (en) 2026-01-08
CA3242577A1 (en) 2023-06-22
KR20240119299A (ko) 2024-08-06
EP4448529A1 (en) 2024-10-23
TW202333676A (zh) 2023-09-01
CN118401525A (zh) 2024-07-26
IL313314A (en) 2024-08-01
JP2024546844A (ja) 2024-12-26
US12012412B2 (en) 2024-06-18
US20230192707A1 (en) 2023-06-22
WO2023114995A1 (en) 2023-06-22
US20240300961A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
AU2019333310B2 (en) Salts and crystal forms of GABAA positive allosteric modulator
US20240300961A1 (en) Solid forms of pyrazolo[3,4-d]pyrimidine compounds
EP4434979A1 (en) Kif18a inhibitor
JP2018172438A (ja) オベチコール酸の調製、使用および固体形態
EP3337485B1 (en) Crystalline forms of ibrutinib
AU2009235440B2 (en) Anhydrous crystal form of orvepitant maleate
CN119013267A (zh) 奥比塞匹布的盐及其制备方法和中间体
AU2022283638B2 (en) Co-crystal forms of a novobiocin analog and proline
JP2023062072A (ja) Ｒｏｒガンマの阻害剤
CN118525016A (zh) 蛋白酪氨酸磷酸酶抑制剂及其使用方法
IL259556B2 (en) Solid forms of substituted 6,5-dihydro-6-phenyl-benzo[f]isoquinoline-2-amine compounds
EP4134369B1 (en) Solid forms of tetrahydropyranyl amino-pyrrolopyrimidinone compounds
US20220235063A1 (en) Morphic forms of marizomib and uses thereof
EA052651B1 (ru) ТВЕРДЫЕ ФОРМЫ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫХ СОЕДИНЕНИЙ
US20120059034A1 (en) Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
US20240247026A1 (en) Salts and crystalline forms of (3e) 3-[o-[(phosphonooxy)methyl]oxime]-pregn-4-ene-3,20-dione and related uses
HK40112450A (zh) 吡唑并[3，4-d]嘧啶化合物的固体形式
WO2026024591A1 (en) Tryptamine prodrug solid forms

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)